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Abstract
Purpose: We devised a new computer-aided diagnosis method to segregate dementia using one estimated index (Total Z
score) derived from the Brodmann area (BA) sensitivity map on the stereotaxic brain atlas. The purpose of this study is to
investigate its accuracy to differentiate patients with Alzheimer’s disease (AD) or mild cognitive impairment (MCI) from
normal adults (NL).
Methods: We studied 101 adults (NL: 40, AD: 37, MCI: 24) who underwent
18FDG positron emission tomography (PET)
measurement. We divided NL and AD groups into two categories: a training group with (Category A) and a test group
without (Category B) clinical information. In Category A, we estimated sensitivity by comparing the standard uptake value
per BA (SUVR) between NL and AD groups. Then, we calculated a summated index (Total Z score) by utilizing the sensitivity-
distribution maps and each BA z-score to segregate AD patterns. To confirm the validity of this method, we examined the
accuracy in Category B. Finally, we applied this method to MCI patients.
Results: In Category A, we found that the sensitivity and specificity of differentiation between NL and AD were all 100%. In
Category B, those were 100% and 95%, respectively. Furthermore, we found this method attained 88% to differentiate AD-
converters from non-converters in MCI group.
Conclusions: The present automated computer-aided evaluation method based on a single estimated index provided good
accuracy for differential diagnosis of AD and MCI. This good differentiation power suggests its usefulness not only for
dementia diagnosis but also in a longitudinal study.
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Introduction
The number of patients with dementia in the world is increasing
every year [1]. Specifically, Alzheimer’s disease (AD) and mild
cognitive impairment (MCI) are worth noticing because AD
accounts for 60% of the dementia population and the probability
of MCI progression to AD is considered 11 to 33% in two years
[2]. On the bright side, a number of promising therapeutic
measures against dementia are under way [3–6], which then
brings the idea that early detection and accurate differentiation are
of great importance. Examination procedures to promote early
detection and facilitate an accurate differential diagnosis include
diagnostic imaging procedures, such as positron emission com-
puted tomography (PET), single photon emission computed
tomography (SPECT), and magnetic resonance imaging (MRI).
In particular,
18FDG PET is useful in patients under a tentative
diagnosis of degenerative brain disease and in early detection of
dementia [7,8]. Although imaging technical advances such as in
vivo visualization of a pathological substance amyloid protein are
now available in AD detection, the usefulness of
18FDG PET,
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25033which facilitates early diagnosis based on the pattern of altered
brain metabolism, is still emphasized [9–19].
There are many computer-aided diagnosis (CAD) tools for
detection of dementia. Among them, 3D-SSP (NEUROSTAT) is a
widely-used imaging tool in the clinical setting [20] in contrast to
statistical parametric mapping (SPM) as rather a research tool [21]
for evaluating the rate of reduction in comparison with normal
group. In particular, 3D-SSP excels in visual assessment of
metabolic changes in the brain. However, when investigating serial
changes in the same patient or therapeutic intervention-related
changes, a more objective analytical method is preferable and
elimination of subjective diagnostic factors such as visual searching
or manipulation of region selection is necessary.
Thus, we aimed to differentiate AD patients from normal
subjects or MCI patients using a new CAD method automatically.
To this end, we first determined 34 BA regions on projected
images of the brain surface in reference to the BA map [22], and
generated sensitivity-distribution maps to compare the standard
uptake value ratio (SUVR) in each brain region among the NL
and AD groups. Finally, we verified the segregation power of this
method by applying it to the MCI group.
Materials and Methods
Subjects
The current study was approved by the Ethics Committee of
Hamamatsu Medical Center, and written informed consent was
obtained from each participant after detail explanation of this
study. We performed PET measurements with
18FDG for all
participants (n=101) and used their
18FDG images for the current
purpose. They consisted of 40 normal volunteers (NL) (18 males,
22 females, mean age: 55.8617.1 years) with normal MR findings
and normal cognition by mini-mental state examination (MMSE)
[23], 37 patients with AD (13 males, 24 females, mean age:
59.466.6 years) diagnosed on the basis of the NINDS-ADRDA
[24] and DSM-IV [25] criteria, and 24 patients with MCI (9
males, 15 females, mean age: 69.269.9 years), who met Peterson’s
criteria for amnestic MCI [26]. All MCI patients were annually
evaluated clinically for 3 years, and 10 amnestic MCI patients (3
males, 7 females) were converted as AD (called as an AD-
converter) and other 14 patients (6 males, 8 females) remained
amnestic MCI (called as a non-converter).
Using the SPSS (Version 17.0) Random Number Generator
Tool, the two groups (NL and AD) were arbitrarily divided into
two categories (Table 1). We confirmed that there were no
significant differences in the age, sex, or MMSE scores between
the two categories (p.0.1). One was a training group for
generation of a sensitivity distribution index (Category A), and
the other was a test group (Category B) for verification of the index
obtained from Category A.
18FDG PET scanning
We used an SHR-12000 Brain PET camera (Hamamatsu
Photonics K.K.) with intrinsic resolution, 2.962.963.4 mm full-
width half-maximum (FWHM), 47 slices obtained simultaneously,
and 163 mm axial field of view [27]. After transmission scan for
attenuation correction was performed for 10 minutes, 1.5 MBq/
kg of
18FDG was injected through the cubital vein. After each
subject rested in a dimly-lit room for 45 minutes, emission was
measured in 2D mode for 15 minutes. The filtered back projection
(FBP) method was employed for image reconstruction. The matrix
and pixel size of the reconstructed image were 1926192647 and
1.361.363.4 mm, respectively.
Demarcation of the Brodmann area
On the brain surface projection atlas (MRI template) from the
3D-SSP tools [20], 34 regions were determined as Brodmann
areas (BAs) [22] by 1 neurologist and 2 radiological technicians
(Fig. 1A). In demarcation of BAs, by referring to the Talairach
Atlas [28] which describes BAs along with the names of gyri, we
reconstructed the BA fields in the axial direction and were able to
allocate BAs on the surface of lateral and medial view of the
spatially normalized brain. In definition, BAs consist of Areas 1 to
52, which are categorized on the basis of neuronal structure in the
cerebral cortex stained in the postmortem brain. In the present
study, we unified BAs 1–3, 29–30, 35–36, and 41–42 as each single
area due to the small pixel count. We had to exclude BA 12, 13,
14, 15, 16, 26, 27, 33, 43, 48, 49, 50, 51, and 52 because of no
visualization on the brain lateral projection surface. By adding the
cerebellum, a total of 34 regions were determined in this study.
Because the characteristic pattern of
18FDG accumulation in
dementia on 3D-SSP map is highlighted in the lateral views [9–
14], we excluded the anterior/posterior/superior/inferior views.
As the right-left difference in
18FDG accumulation is not a critical
matter in the AD diagnosis, the bilateral values were treated as a
mean single value in the present study.
Image analysis
Using a 3D-SSP anatomical standardization tool,
18FDG PET
images were normalized to Talairach’s standard brain images
[28]. Subsequently, peripheral noises outside the brain were
removed using standard brain mask images, and the mean whole-
brain pixel count in the standard brain (standard uptake value
(SUV)) was calculated. Based on the mean SUV for the standard
brain in the NL group in Category A, each pixel was corrected as
the SUV ratio (SUVR) by dividing all pixels by SUV of the whole
brain. Some researchers assume the pons as an area of the
reference for SUV normalization in 3D-SSP. However, the global
mean is considered as a better index for the normalization than the
pons due to the less occurrence of misregistration of ROI on the
small area pons. The accuracy of our method was dependent on
the value in the NL group, in which the smaller variation of mean
value was more important. Therefore, the whole brain was chosen
as the region for correction of the count normalization.
On projected images of the brain surface, we determined the
mean SUVR for each BA, and then calculated the mean SUVR
and standard deviation per BA in the NL group in Category A.
Using these values and equation (1), the SUVR was converted to
the Z-score per BA (ZNL_n, n=Area number); here, Z-score per
area (not Z-score per pixel) was calculated.
ZNL n~
SUVRn{MeanNL n
SDNL n
ðEq:1Þ
SUVRn indicates the SUVR for Area n in a subject. The
MeanNL_n and SDNL_n were the mean SUVR and standard
deviation in the NL group of Category A, respectively.
Sensitivity
In Category A, the ZNL_n values for each BA were compared
between NL and AD subjects. We calculated sensitivity using a cut-
off value determined from SUVRs for the NL group of Category A
by measuring the amount of SUVR values lower than the cut-off in
the AD group. The cut-off value was determined as ZNL_n=21.0,
because the proportion of ZNL_n values of -1.0 or more in all values
was 0.8413 in the standard normal distribution table; the specificity
of NL assessment may be fixed at approximately 80%. The
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experiments, in which changes in cut-off value caused to affect the
final accuracy. The value 21.0 was found good enough to
guarantee above 80% specificity considering the Z-score distribu-
tion. The sensitivity per BA, which reflects the diagnostic capacity
for AD, was calculated (WNL-AD_1 to WNL-AD_34).
Total Z-score method
In practice, no radiologist would diagnose diseases only by
looking at an abnormality of a single domain of the brain. Instead,
they dedicate themselves to visual searching for every part of the
brain and make a judgment through the comprehensive
inspection. To eliminate this laborious work, in this study, we
devised the Total Z-score method, which allows physicians to
make a diagnosis based on the comprehensive assessment of all
areas without focusing on each BA.
First, we estimated the weighted sensitivity per area. By
inserting this value and each subject’s Z-score into the following
equation (2), all areas may be comprehensively evaluated based on
a single value. As SumNL-AD is multiplied by the sensitivity value
per BA, the site of disease-specific reduction may be emphasized,
improving the diagnostic capacity:
SumNL{AD~
X 34
n~0
ZNL n:WNL{AD n ðEq:2Þ
ZNL_n indicates the Z-score for Area n in a subject. It is based on
data from the NL group in Category A. WNL-AD_n refers to the
sensitivity to differentiate AD from NL in Area n. In all subjects,
values were inserted into the equation (2), and SumNL-AD was
calculated in each subject.
Table 1. Subject characteristics.
Group NL AD MCI
Category A B A B AD-converters Non-converters
Number 20 20 18 19 10 14
Male/Female 9/11 9/11 6/12 7/12 3/7 6/8
Age (years) 56.0615.4 55.7619.1 59.467.5 59.365.7 64.569.5 72.669.0
MMSE* (score) 29.061.1 29.161.1 16.765.4 16.565.1 23.763.4 26.661.4
*MMSE=mini-mental state examination.
doi:10.1371/journal.pone.0025033.t001
Figure 1. BA on 3D-SSP images. BA on 3D-SSP MRI template images (A) and sensitivity-distribution maps of BA on 3D-SSP images among NL and
AD in Category A (B). The color bar denotes the levels of sensitivity to differentiate NL and AD in Category A.
doi:10.1371/journal.pone.0025033.g001
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(ZNL-AD) based on the mean/standard deviation in the NL group
of Category A. The MeanNL-AD and SDNL-AD were a mean value
of ZNL-AD and its standard deviation in the NL group of Category
A, respectively.
ZNL{AD~
SumNL AD{MeanNL{AD
SDNL AD
ðEq:3Þ
Thus, the Total Z-score, which reflects the comprehensive
evaluation of the SUVRs or 34 BAs on brain surface projections,
ZNL-AD was calculated in each subject. A high ZNL-AD value
suggests an NL condition, whereas a low value suggests AD.
The value SumNL-AD was generated by adding 34 products
of multiplication of ZNL_n by WNL-AD_n, where the sensitivity
WNL-AD_n was used as a weighted index. For instance, in a brain
region that clearly differs NL from AD, ZNL_n in NL subjects is
high while ZNL_n in AD patients is low, resulting in the sensitivity
WNL-AD_n being high. Thus, the index WNL-AD_n makes the
difference of SumNL-AD between NL and AD more remarkable by
weighting the value ZNL_n. In contrast, in an area with negligible
difference between NL and AD, there is no significant gap in
ZNL_n of NL and AD, resulting in the sensitivity WNL-AD_n being
low. This makes the product (ZNL_n 6WNL-AD_n) much smaller.
Then, the product SumNL-AD is converted to ZNL-AD using Eq. 3.
In this way, an initial determinant (a cut-off value) can differentiate
groups by weighting values in each brain area.
NL-AD differentiation
Using the Total Z-score (ZNL-AD), differential analysis of NL
and AD was conducted to evaluate the accuracy. Before this
differentiation was performed, we determined a cut-off value with
which NL-AD pair was compared using the SPSS software
(Version 17.0). We estimated a receiver operating characteristic
curve (ROC) and the area under the curve (AUC) based on the
ZNL-AD values for the NL and AD groups in Category A. The most
appropriate cut-off value (CNL-AD) was determined by the Youden
index [29–31]. Based on CNL-AD, Categories A and B were
classified into NL or AD, respectively, to evaluate the accuracy.
Application to MCI
We applied this method using ZNL-AD and CNL-AD to
18FDG
PET images of amnestic 24 MCI patients scanned at entry to
verify the usefulness of this program in differentiation of AD from
MCI.
Results
3D-SSP Z-score images
In the NL group in Category A, the mean SUV for the standard
brain was 5.75. Employing these subjects as a reference database,
all subjects’ 3D-SSP Z-scores were calculated by pixel and average
3D-SSP Z-score images were prepared in 20 NL (Fig. 2A) and 18
AD (Fig. 2B) subjects in Category A, as well as in 20 NL (Fig. 2C)
and 19 AD (Fig. 2D) subjects in Category B, respectively. As
shown Figure 2, in the NL and AD groups, there was no marked
difference between Categories A and B. In the NL group, there
was no marked reduction in either group. In the AD group, there
were marked decreases in the lateral parietal, lateral temporal and
cingulate gyrus area. Additionally, average images were prepared
in all 24 MCI (Fig. 2E), 10 AD-converter (Fig. 2F) and 14 non-
converter (Fig. 2G), respectively. In the MCI patients, there were
greater decreases of glucose metabolism in the lateral parietal,
lateral temporal and medial parietal areas in AD-converters than
non-converters
BA-based analysis
The quantitative SUVRs in the NL and AD groups in Category
A are shown in Table 2. There were significant differences in the
SUVRs for BAs 7, 19, 21, 22, 23, 31, 37, 39, 40, and 41 (42)
between the NL and AD groups (p,0.001). In the AD group, the
mean SUVRs of each BA region were 20, 13, 15, 8, 23, 22, 16, 17,
17, and 10% lower than those in the NL group, respectively.
As shown in Table 2 (sensitivity), the WNL-AD value for BA 31
was the highest (100%), followed by 94.4% for BAs 7/40, 88.9%
for BAs 19/23, and 83.3% for BAs 21/39/40(41). As illustrated in
the Figure 2, the maps show the distribution of the sensitivity to
differentiate NL from AD. Figure 1B shows the sensitivity of each
BA with a gray scale, in which the black indicates higher
sensitivity.
Comparison between NL and AD groups
To perform the 2-group differential analysis of NL and AD, we
estimated the cut-off value (CNL-AD) based on the ZNL-AD values.
First, we made the dot plots (Fig. 3A) of ZNL-AD in the NL and AD
groups in Category A, and the AUC was calculated to be 1.00. As
a result, the most appropriate cut-off value (CNL-AD) was
determined to be 21.9 by the Youden index. Furthermore, we
evaluated the differentiation power by CNL-AD, and the sensitivity
and specificity in Category A were found to be all 100%.
Using equations (1) to (3) and the sensitivity-distribution maps
(Fig. 1B) based on SUVRs of NL and AD groups in Category A,
ZNL-AD of each subject in Category B were calculated (Fig. 3B). In
Category B, the sensitivity and specificity were found to be 100%
and 95%, respectively.
Detection of AD in the MCI group
We made the dot plots of ZNL-AD in 24 MCI patients who had
been classified into two groups; AD-converters and non-converters
diagnosed clinically during the 3-year follow-up period. Using the
cut-off value determined in the Category A (CNL-AD), our program
judged 9 patients as AD (38%) and 15 patients as NL (62%).
During the 3-year follow-up, 10 patients were converted from
MCI to AD (AD-converters) and the residual 14 MCI patients
were still under the MCI condition. As shown in Figure 3C, 8 out
of 10 AD-converters were determined as AD by our program
(80%), and 2 out of 10 AD-converters as NL (20%). In contrast, 13
out of 14 non-converters were determined as NL by our program
(93%), and 1 out of 14 as AD (7%). This yielded the sensitivity and
specificity for differentiating AD-converters from non-converters
in MCI patients by our CAD program to be 80% and 93%,
respectively, with an accuracy of 88%.
Discussion
In this study, we developed a new CAD analytic tool using BA
compartmentalization on 3D-SSP atlas, and calculated the Total
Z-score through the complex observation of all areas based on the
sensitivity (weighted value) per area to investigate the differential
accuracy of images. When employing this method, the sensitivity
and specificity for differentiating AD from NL were all 100%, in
the training group, with an accuracy of 100%. In the test group,
they were found to be 100 and 95%, respectively, with an accuracy
of 98%. Furthermore, the sensitivity and specificity for differen-
tiating AD-converters from non-converters in patients with MCI
were 80% and 93%, respectively, with an accuracy of 88%. As
shown in Fig. 1 and Table 2, the sensitivity (WNL-AD_n) map
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AD in the previous literature [8–14]; hypometabolism in the
parietal (BAs 7, 19, 39, and 40), temporal (BAs 21, 22, 37, and 41
(42)), and cingulate (BAs 7, 23, and 31) areas in patients with AD.
A CAD method is never new now, but the level of its accuracy is
still a target of improvement. Previous CAD methods using both
statistical mapping technique and ROI analysis reported about
high accuracy for differentiating AD from NL [32,33]. These
methods used specific ROIs or combination of multiple ROIs to
discriminate one group from another. In contrast, our method
used all ROIs (BAs) to estimate one unified value as a Total Z-
score that was the product of the sensitivity of each ROI. This
method consisting of more objective and CAD-oriented algorism
can eliminate any subjective errors and bias and enables more
accurate and objective diagnosis than those other methods.
Indeed, the present method generated 98% in accuracy for
discriminating AD from NL.
This program affording a high segregation power was also
shown to be effective to extract AD-like images from the group of
MCI, resulting in good accuracy (88%) for differentiating AD-
converters from non-converters. Previous CAD methods were
reported to exhibit up to 90% in accuracy for differentiating AD-
converters from non-converters [34–36] among MCI patients.
However, ROI assessment embedded in their programs seemed
less objective than our method. As shown in Figure 2, 3D-SSP
provided visual presentations characteristic to AD-converters
(Fig. 2F) and non-converters (Fig. 2G), where there were greater
decreases of glucose metabolism in the lateral parietal (BAs 7, 39,
and 40), lateral temporal (BAs 21 and 37), and medial (BAs 7 and
31) areas in AD-converters than non-converters. Our method
enabling objective assessment using a Total Z-score value without
visual inspection showed the BAs distribution similar to the high
sensitivity areas in the sensitivity-distribution maps (Fig. 1B). It is
worth noting that an MCI patient with a high chance of AD
conversion would show such a hypometabolic pattern seen in
those BAs. Although the conversion rate from MCI to AD was
reported to be 11–33% [2], the rate (42%) in our study was shown
to be higher possibly because the observation period for disease
conversion was one year longer in our study. Because we did know
who were converted as AD during the 3-year follow-up, we were
able to calculate the sensitivity and accuracy of this method in
differentiation of AD from MCI by comparing the number of
program-based AD patients with that of clinically diagnosed AD-
converters.
Figure 2. 3D-SSP images. Employing 20 NL subjects in Category A as a reference database, all subjects’ 3D-SSP Z-score images were prepared.
Average Z-score images of 20 NL (A) and 18 AD (B) in Category A. Average Z-score images of 20 NL (C) and 19 AD (D) in Category B. Average Z-score
images of a total of 24 MCI (E), 10 AD-converters (F) and 14 non-converters (G). The color bar denotes the levels of Z-score based on 20 NL subjects in
Category A.
doi:10.1371/journal.pone.0025033.g002
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they used a channelized Hotelling observer (CHO) method or a
principal component analysis (PCA) after setting volume of interests
(VOIs) for diagnosing AD or MCI. The merit of using CHO [37] is
to differentiate patterns of frequency after Fourier transformation of
levels of pixels measured by SPECT between groups. Using voxel
data [37,38] sounds more objective, but a high chance of noise
generation may degrade the image quality. In contrast, the use of
VOI that contains multiple pixels would improve the reliability of
segregation.Some researchersused PCAforfixed ROIs determined
a priori [39–41], where relatively lower sensitivity and specificity
were reported than those of our study. One reason of our high
accuracy may be the fact that all our ROI data were converted to
the sensitivity values irrespective of regions of specificity, although
PCA needs to select the region specific to the disease beforehand.
Indeed, our preliminary data using PCA for our ROI data
generated 5,10% reduction in accuracy (data not shown). In
addition, our CAD advantage is the flexibility in applying this
method to any disease segregation because a priori ROI
determination is unnecessary.
There were methodological issues to be noted in our CAD
method. Our program takes advantage of the patterns of regional
sensitivity to differentiate AD from NL, and the generated sensitivity-
distribution map (Fig. 1B) is a core of our method. Any core map
Figure 3. The dot plots of Total Z-score. The dot plots of ZNL-AD in Category A (A), ZNL-AD in Category B (B), and AD-converters (MCI+) and non-
converters (MCI-) (C).
doi:10.1371/journal.pone.0025033.g003
Table 2. SUVR and sensitivity of Brodmann area.
No.
Brodmann
area SUVR*
Sensitivity
(%) No. Brodmann area SUVR Sensitivity (%)
NL AD WNL-AD_n NL AD WNL_AD_n
1 1, 2, 3 6.8160.30 7.2560.51 11.1 18 25 6.8860.28 7.4960.64 0
2 4 6.9960.25 7.6460.48 0 19 28 3.4460.29 3.9360.29 0
3 5 7.0360.48 7.3860.61 5.6 20 29, 30 6.6460.50 6.3160.44 44.4
4 6 7.3260.24 7.4860.49 5.6 21 31 8.7660.42 7.2060.65 100
5 7 7.4960.32 6.2660.60 94.4 22 32 6.7660.31 6.9560.55 16.7
6 8 7.3660.33 7.3760.37 5.6 23 34 4.1460.39 4.3860.30 5.6
7 9 7.1260.27 7.1060.37 16.7 24 35, 36 4.6360.29 4.8460.39 5.6
8 10 7.0260.26 7.1360.47 22.2 25 37 7.2060.24 6.2160.73 72.2
9 11 6.6060.27 7.0260.53 5.6 26 38 5.7660.20 5.8060.31 16.7
10 17 8.0360.60 8.0160.65 22.2 27 39 7.3160.27 6.2460.67 83.3
11 18 7.5960.38 7.4060.60 33.3 28 40 7.0460.23 6.0160.48 94.4
12 19 8.7560.36 7.7560.61 88.9 29 41, 42 7.2060.28 6.5560.45 83.3
13 20 5.8460.19 5.6460.41 38.9 30 44 7.1560.27 7.1260.40 33.3
14 21 7.0660.26 6.1460.60 83.3 31 45 7.0760.23 7.2360.44 22.2
15 22 7.2160.27 6.7060.32 77.8 32 46 7.0160.26 7.1060.43 22.2
16 23 7.6360.46 6.1960.73 88.9 33 47 6.6460.26 6.8760.46 16.7
17 24 5.8960.39 5.6060.54 44.4 34 CBL** 5.9960.33 6.7460.48 0
*SUVR: standard uptake value ratio (mean 6 SD).
**CBL: cerebellum.
doi:10.1371/journal.pone.0025033.t002
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sensitivity would lead to misdiagnosis. This kind of error may reflect
intrinsic limitations of any automated imaging analyses including
CAD technique because a pixel-value within a ROI has to be
determined by a threshold. Therefore, although our method is useful
and helpful in differential diagnosis of amnesic diseases, any CAD-
induced outcomes should be accompanied with detailed clinical
assessment to minimize misdiagnosis in the clinical setting. A good
point of another issue is its versatility. In this study, our program is not
designated as a tool for discriminating MCI from NL. If this
segregation is a target, the Total Z-score ZNL-MCI from the sensitivity-
distribution maps among the NL and MCI groups may be
appropriate. To evaluate the differentiation power of the Total Z-
score ZNL-MCI, we made sensitivity-distribution maps (Fig. 4A)
between NL in Category A and MCI group. Using these maps and
Equation (1) to (3) by changing AD data into MCI data, we calculated
the Total Z-score ZNL-MCI (Fig. 4B). Employing the Youden index,
cut-off values showing the most accurate differential diagnostic
capacity was calculated: CNL-MCI=21.3. In addition, the area under
the curve (AUC) value was 0.87 (Fig. 4C). In any case, this BA-based
procedurehas a potential to be applied for the differential diagnosis of
many other brain diseases such as FTD and DLB with a specific
pattern of neuronal degeneration.
In conclusion, our newly developed CAD method has a good
power to discriminate AD from NL with an accuracy of 98%. This
program also showed a good performance in detecting AD-
converters among amnestic MCI patients with an accuracy of
88%. These results suggest the usefulness of this procedure for the
differential diagnosis of AD/MCI as a diagnosis-assisting method
free of any human judgment. Because the calculated Total Z-score
is an objective value, our method with this index enables the semi-
quantitative assessment of metabolic reduction and follow-up in
dementia. This BA-based procedure can be also applied for the
differential diagnosis of many other brain diseases such as FTD
and DLB with a specific pattern of neuronal degeneration.
Acknowledgments
We acknowledge the staff of Hamamatsu Medical Center for data
acquisition and the differential diagnosis of all subjects.
Author Contributions
Conceived and designed the experiments: AK YK YO. Performed the
experiments: AK SI. Analyzed the data: AK YK SI. Contributed reagents/
materials/analysis tools: AK YK SI EY HO SN SM YO. Wrote the paper:
AK SN YO.
Figure 4. Sensitivity-distribution maps among NL and MCI. Sensitivity-distribution maps of BA (A), dot plots (B), and ROC (C) between NL and
MCI. The color bar denotes the levels of sensitivity to differentiate NL in Category A and MCI groups.
doi:10.1371/journal.pone.0025033.g004
New Computer-Aided Diagnosis of Dementia
PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e25033References
1. Prince M, Jackson J (2009) World Alzheimer Report 2009 Executive Summary.
Alzheimer’s Disease 2009.
2. Ritchie K (2004) Mild cognitive impairment: an epidemiological perspective.
Dialogues Clin Neurosci 6: 401–407.
3. Cummings JL (2000) Cholinesterase inhibitors: A new class of psychotropic
compounds. Am J Psychiatry 157: 4–15.
4. Schenk D (2002) Amyloid-beta immunotherapy for Alzheimer’s disease: the end
of the beginning. Nat Rev Neurosci 3: 824–828.
5. Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, et al. (2006) Effects
of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer
disease. Neurology 66: 602–604.
6. Citron M (2004) Strategies for disease modification in Alzheimer’s disease. Nat
Rev Neurosci 5: 677–685.
7. Silverman DH, Gambhir SS, Huang HW, Schwimmer J, Kim S, et al. (2002)
Evaluating early dementia with and without assessment of regional cerebral
metabolism by PET: a comparison of predicted costs and benefits. J Nucl Med
43: 253–266.
8. Li Y, Rinne JO, Mosconi L, Pirraglia E, Rusinek H, et al. (2008) Regional
analysis of FDG and PIB-PET images in normal aging, mild cognitive
impairment, and Alzheimer’s disease. Eur J Nucl Med Mol Imaging 35:
2169–2181.
9. Mosconi L (2005) Brain glucose metabolism in the early and specific diagnosis of
Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol
Imaging 32: 486–510.
10. Nestor PJ, Fryer TD, Smielewski P, Hodges JR (2003) Limbic hypometabolism
in Alzheimer’s disease and mild cognitive impairment. Ann Neurol 54: 343–351.
11. De Santi S, de Leon MJ, Rusinek H, Convit A, Tarshish CY, et al. (2001)
Hippocampal formation glucose metabolism and volume losses in MCI and AD.
Neurobiol Aging 22: 529–539.
12. De Leon MJ, Convit A, Wolf OT, Tarshish CY, De Santi S, et al. (2001)
Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-
deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad
Sci U S A 98: 10966–10971.
13. Mosconi L, Tsui WH, De Santi S, Li J, Rusinek H, et al. (2005) Reduced
hippocampal metabolism in MCI and AD: automated FDG-PET image
analysis. Neurology 64: 1860–1867.
14. Mosconi L, De Santi S, Li Y, Li J, Zhan J, et al. (2006) Visual rating of medial
temporal lobe metabolism in mild cognitive impairment and Alzheimer’s disease
using FDG-PET. Eur J Nucl Med Mol Imaging 33: 210–221.
15. Ishii K, Sakamoto S, Sasaki M, Kitagaki H, Yamaji S, et al. (1998) Cerebral
glucose metabolism in patients with frontotemporal dementia. J Nucl Med 39:
1875–1878.
16. Jeong Y, Cho SS, Park JM, Kang SJ, Lee JS, et al. (2005) 18F-FDG PET
findings in frontotemporal dementia: an SPM analysis of 29 patients. J Nucl Med
46: 233–239.
17. Diehl-Schmid J, Grimmer T, Drzezga A, Bornschein S, Riemenschneider M,
et al. (2007) Decline of cerebral glucose metabolism in frontotemporal dementia:
a longitudinal 18F-FDG-PET-study. Neurobiol Aging 28: 42–50.
18. Albin RL, Minoshima S, D’Amato CJ, Frey KA, Kuhl DA, et al. (1996) Fluoro-
deoxyglucose positron emission tomography in diffuse Lewy body disease.
Neurology 47: 462–466.
19. Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, et al. (2001)
Alzheimer’s disease versus dementia with Lewy bodies: cerebral metabolic
distinction with autopsy confirmation. Ann Neurol 50: 358–365.
20. Minoshima S, Koeppe RA, Frey KA, Kuhl DE (1994) Anatomic standardiza-
tion: linear scaling and nonlinear warping of functional brain images. J Nucl
Med 35: 1528–1537.
21. Friston K, Ashburner J, Kiebel S, Nichols T, Penny W (2006) Statistical
Parametric Mapping: The Analysis of functional Brain Images. ELSEVIER. pp
92–98.
22. Laurence J (2005) Brodmann’s Localisation in the Cerebral Cortex. Springer. pp
105–126.
23. Cockrell JR, Folstein MF (1988) Mini-Mental State Examination (MMSE).
Psychopharmacol Bull 24: 689–692.
24. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, et al. (2001) Current
concepts in mild cognitive impairment. Arch Neurol 58: 1985–1992.
25. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984)
Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work
Group under the auspices of Department of Health and Human Services Task
Force on Alzheimer’s Disease. Neurology 34: 939–944.
26. American Psychiatric Association (1994) Diagnostic and Statistical Manual of
Mental Disorders Fourth Edition (DSM-IV). Washington, DC: American
Psychiatric Association. pp 143–147.
27. Watanabe M, Shimizu K, Omura T, Takahashi M, Kosugi T, et al. (2002) A
new high resolution PET scanner dedicated to brain research. IEEE Trans Nucl
Sci 49: 634–639.
28. Talairach J, Tournoux P (1988) Co-planar Stereotaxic Atlas of the Human
Brain: 3-Dimensional Proportional System - an Approach to Cerebral Imaging.
New York: Thieme Medical. pp 9–18.
29. Perkins NJ, Schisterman EF (2006) The inconsistency of ‘‘optimal’’ cutpoints
obtained using two criteria based on the receiver operating characteristic curve.
Am J Epidemiol 163: 670–675.
30. Fluss R, Faraggi D, Reiser B (2005) Estimation of the Youden Index and its
associated cutoff point. Biom J 47: 458–472.
31. Akobeng AK (2007) Understanding diagnostic tests 3: Receiver operating
characteristic curves. Acta Paediatr 96: 644–647.
32. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE (1995) A diagnostic
approach in Alzheimer’s disease using three-dimensional stereotactic surface
projections of fluorine-18-FDG PET. J Nucl Med 36: 1238–1248.
33. Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, et al. (2008) Multicenter
standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzhei-
mer’s disease, and other dementias. J Nucl Med 49: 390–398.
34. Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H,
et al. (2005) Prediction of individual clinical outcome in MCI by means of
genetic assessment and (18)F-FDG PET. J Nucl Med 46: 1625–1632.
35. Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, et al. (2004) MCI
conversion to dementia and the APOE genotype: a prediction study with FDG-
PET. Neurology 63: 2332–2340.
36. Anchisi D, Borroni B, Franceschi M, Kerrouche N, Kalbe E, et al. (2005)
Heterogeneity of brain glucose metabolism in mild cognitive impairment and
clinical progression to Alzheimer disease. Arch Neurol 62: 1728–1733.
37. Shidahara M, Inoue K, Maruyama M, Watabe H, Taki Y, et al. (2006)
Predicting human performance by channelized Hotelling observer in discrim-
inating between Alzheimer’s dementia and controls using statistically processed
brain perfusion SPECT. Ann Nucl Med 20: 605–613.
38. Salmon E, Kerrouche N, Perani D, Lekeu F, Holthoff V, et al. (2009) On the
multivariate nature of brain metabolic impairment in Alzheimer’s disease.
Neurobiol Aging 30: 186–197.
39. Rodriguez G, Nobili F, Copello F, Vitali P, Gianelli MV, et al. (1999) 99mTc-
HMPAO regional cerebral blood flow and quantitative electroencephalography
in Alzheimer’s disease: a correlative study. J Nucl Med 40: 522–529.
40. Scarmeas N, Habeck CG, Zarahn E, Anderson KE, Park A, et al. (2004)
Covariance PET patterns in early Alzheimer’s disease and subjects with
cognitive impairment but no dementia: utility in group discrimination and
correlations with functional performance. Neuroimage 23: 35–45.
41. Nobili F, Salmaso D, Morbelli S, Girtler N, Piccardo A, et al. (2008) Principal
component analysis of FDG PET in amnestic MCI. Eur J Nucl Med Mol
Imaging 35: 2191–2202.
New Computer-Aided Diagnosis of Dementia
PLoS ONE | www.plosone.org 8 September 2011 | Volume 6 | Issue 9 | e25033